Summary
In a significant market movement during September 2018, Genomics was the subject of a vc funding. The transaction achieved a gross valuation of £25,000,000. Leading the round was Lansdowne Partners, Tanarra, Invesco Perpetual, Woodford Investment Management Ltd, Oxford Sciences Innovation, Vertex Pharmaceuticals. IP Group plc.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Lansdowne Partners
Lead Investor / Acquirer
Tanarra
Lead Investor / Acquirer
Invesco Perpetual
Lead Investor / Acquirer
Woodford Investment Management Ltd
Lead Investor / Acquirer
Oxford Sciences Innovation
Lead Investor / Acquirer
Vertex Pharmaceuticals. IP Group plc
Advising Broker
Undisclosed Firm
Related Deals in Software & SaaS
Series B prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in